In a year since the start of the Covid-19 pandemic, progress has been made in knowledge of the SARS CoV-2 virus and in research.
The team from the genetics laboratory doctor of the University of Rome Tor Vergata led by prof. Giuseppe Novelli, internationally renowned Italian geneticist, is carrying out a research on the genetic variant linked to the more severe forms of Covid-19 signed by the Covidhge International Genetics Consortium, in collaboration with the Bambino Gesù pediatric hospital in Rome. The research, the first in this area that also aims to contribute to the development of personalized therapies, was published in the prestigious journal Science and it's considered among the top 10 scientific discoveries of 2020.
How much does genetic variability affect the development of the disease? What emerged from the first results of the international study?
Could a deficiency in the innate barrier be the cause of severe virus symptoms?
Could a strong immune response be enough to not contract the SARS CoV-2 virus?
Monoclonal antibody based therapies for high-risk patients in the early stage Covid-19 authorized and available to date are those produced in the United States. It has been shown that monoclonal antibodies are useful in an initial phase of the disease, but other studies are being conducted to verify, in different quantities and ways, their effectiveness even in the advanced phase. The Italian team led by prof. Novelli is also collaborating with the University of Toronto to one study on monoclonal antibodies and are in negotiations with a pharmaceutical industry for production for the purpose of experimentation.
What is the action of monoclonal antibodies? Are they effective against mutations?
We talk about it in the video interview with Prof. Giuseppe Novelli, director of the medical genetics laboratory of the Tor Vergata University of Rome at the head of the research team.